26 September, 2017
Other hedge funds have also modified their holdings of the company. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. BlackRock Inc. grew its holdings in Zimmer Biomet Holdings by 4,042.4% in the first quarter. Over the last week of the month, it was -0.93%, -11.38% over the last quarter, and -5.19% for the past six months. Caxton Associates LP bought a new position in shares of Zimmer Biomet Holdings during the 1st quarter valued at about $403,000. To cut down amount of noise on price chart, shares of firm has 20 days moving average price of -1.45% from last close price of 113.06 and act as support or resistance of price limit. Harbour Capital Advisors LLC grew its holdings in Zimmer Biomet Holdings by 13,131.3% in the second quarter. (NYSE:ZBH) presently has a 10 month price index of 1.14218. JPMorgan Chase & Co. lifted its holdings in Zimmer Biomet Holdings by 92.7% during the 2nd quarter. IHT Wealth Management LLC lifted its holdings in Zimmer Biomet Holdings by 28.4% in the 1st quarter.
ZBH has been the topic of several recent research reports. The VC1 of Zimmer Biomet Holdings, Inc. Stifel Nicolaus reaffirmed a "hold" rating and issued a $125.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th.
Analysts on average have given a price target of $135.65 to Zimmer Biomet Holdings, Inc.
The ERP5 Rank is an investment tool that analysts use to discover undervalued companies.
ILLEGAL ACTIVITY NOTICE: "Somewhat Positive Media Coverage Somewhat Unlikely to Impact Zimmer Biomet Holdings (ZBH) Share Price" was reported by StockNewsTimes and is the sole property of of StockNewsTimes. They set a "buy" rating and a $142.00 price target for the company.
According to the Recommendation Trends of the stock polled by Finviz, the company has a consensus recommendation of 2.1 out of the scale from 1 to 5 where 1 stands for Buy and 5 means Sell. The stock has a consensus rating of "Hold" and a consensus price target of $136.58. If you are accessing this story on another site, it was copied illegally and republished in violation of global trademark and copyright law. The correct version of this article can be read at https://www.truebluetribune.com/2017/09/25/zimmer-biomet-holdings-inc-zbh-is-birch-hill-investment-advisors-llcs-10th-largest-position.html.
Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is 3388. A company with a low rank is considered a good company to invest in. The Volatility 12m of Zimmer Biomet Holdings, Inc. If the ratio is greater than 1, then that means there has been an increase in price over the month. For this ZBH's 20 days and 50 days MA (moving average) comparison clear the blur picture. The Gross Margin Score of Zimmer Biomet Holdings, Inc. The firm's revenue was up 1.1% on a year-over-year basis. Comparatively, ZBH posted earnings of $2.02 per share in the same quarter, a year earlier.
Past 5 years growth of UA observed at -, and for the next five years the analysts that follow this company is expecting its growth at 5.00%. BidaskClub lowered Zimmer Biomet Holdings from a "hold" rating to a "sell" rating in a report on Tuesday, August 1st.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be issued a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 annualized dividend and a yield of 0.84%. Zimmer Biomet Holdings's dividend payout ratio is now 27.59%. Finally, Wells Fargo & Company reaffirmed a "market weight" rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. A ratio lower than one shows that the price has decreased over that time period. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year.
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.